-
Company Insights
Innovation and Patenting activity of IVERIC bio Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of IVERIC bio Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
Choroidal Neovascularization Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Choroidal Neovascularization Clinical Trials Market Overview The Choroidal Neovascularization clinical trial market research report provides an overview of the Choroidal Neovascularization Clinical trials scenario. This report provides top-line data relating to the clinical trials on Choroidal Neovascularization and includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report also offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type. It...
-
Company Profile
IVERIC bio Inc – Company Profile
IVERIC bio Inc (IVERIC bio) is a biopharmaceutical company that develops novel therapeutics to treat ophthalmic diseases with a focus on age-related and orphan retinal diseases. The company’s products include Zimura, a complement inhibitor for stargardt disease. It provides Fovista, an anti-platelet-derived growth factor (PDGF). IVERIC bio offers gene therapy research programs, dry age-related macular degeneration and ophthalmic orphan programs. The company seeks to collaborate with companies and academic institutions to develop gene therapy product candidates and other technologies. It...
Add to Basket -
Product Insights
Retinitis Pigmentosa (Retinitis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Retinitis Pigmentosa (Retinitis) Pipeline Drugs Market Report Overview Retinitis Pigmentosa (RP) refers to a group of diseases that cause a slow but progressive vision loss. Retinitis pigmentosa is caused by a genetic defect. Symptoms include night blindness and loss of peripheral vision. The predisposing factors include autosomal dominant inheritance, autosomal recessive inheritance, and x-linked inheritance. The Retinitis Pigmentosa pipeline drugs market research report provides comprehensive information on the therapeutics under development for Retinitis Pigmentosa, complete with analysis by stage of...
-
Product Insights
Usher Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Usher syndrome is an inherited condition characterized by hearing impairment and progressive vision loss. The major symptoms of Usher syndrome are hearing loss and an eye disorder called retinitis pigmentosa. Risk factors include retinal degeneration and prolonged and unprotected exposure to sunlight may accelerate vision loss. Treatment includes cochlear implants, hearing aids, and Vitamin A supplementation. The Usher syndrome pipeline market research report provides comprehensive information on the therapeutics under development for Usher syndrome, complete with analysis by stage of...
-
Product Insights
Net Present Value Model: Zimura
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Zimura Drug Details Avacincaptad pegol sodium...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – avacincaptad pegol sodium
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry avacincaptad pegol sodium Drug Details Avacincaptad pegol sodium (ARC1905) is under development for the...
-
Product Insights
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The Complement C5 pipeline drugs market research report outlays comprehensive information on the Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also reviews key players involved in Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics development with respective active and dormant...
-
Sector Analysis
Contract Injectable Packaging Trends in the Bio/Pharma Industry
Injectables and their packaging requirements are very important to marketed treatments given the volume of vaccines required to tackle the COVID-19 pandemic and the rising number of biologics in development pipelines and on the market. Most injectable drugs in the development pipeline are biologics, which will become increasingly approved and more established in the treatment landscape in the future. The top contract packaging organizations (CPOs) for injectables by the number of contracts are standalone packagers along with large CMOs which...
-
Product Insights
Leber Congenital Amaurosis (LCA) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Leber Congenital Amaurosis (LCA) is the most common cause of inherited blindness in childhood. Its symptoms include vision loss, roving eye movements, deep-set eyes, developmental delay, epilepsy, and motor skill impairment. The Leber Congenital Amaurosis pipeline market research report provides comprehensive information on the therapeutics under development for Leber Congenital Amaurosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of...